This brand name is authorized in Malta
The drug LIDOPROCTENE contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Lidocaine
UNII V13007Z41A - LIDOCAINE HYDROCHLORIDE
|
|
Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane. |
|
2
Hydrocortisone
UNII 3X7931PO74 - HYDROCORTISONE ACETATE
|
|
Hydrocortisone is the main glucocorticoid secreted by the adrenal cortex. Hydrocortisone is an anti-inflammatory steroid. Its anti-inflammatory action is due to reduction in the vascular component of the inflammatory response and reduction in the formation of inflammatory fluid and cellular exudates. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C05AA01 | Hydrocortisone | C Cardiovascular system → C05 Vasoprotectives → C05A Agents for treatment of hemorrhoids and anal fissures for topical use → C05AA Corticosteroids |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: MT | Medicines Authority | Identifier(s): AA1474/00101 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
